RTC-5

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

RTC-5 (TRC-382) 是一种具有抗癌效力的优化吩噻嗪。RTC-5 显示针对 EGFR 驱动的癌症的异种移植模型的功效，其效果归因于 PI3K-AKT 和 RAS-ERK 信号传导的负调节。

RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.

RTC-5 (0-40 μM; 48 hours) inhibits H1650 lung adenocarcinoma cell growth with an GI50 of 12.6μM.RTC-5 (20-40 μM; 24 hours) negatively regulates PI3K-AKT and RAS-ERK pathways by decreasing phospho-AKT and phospho-ERK levels expression.Cell Viability AssayCell Line:H1650 lung adenocarcinoma cells Concentration:0 μM, 1 μM, 10 μM, 20 μM, 30 μM, 40 μM Incubation Time:48 hours Result:Inhibited H1650 lung adenocarcinoma cell growth. Western Blot Analysis Cell Line:H1650 lung adenocarcinoma cells Concentration:20 μM, 40 μM Incubation Time:24 hours Result:Decreased p-AKT, p-ERK expression.

——

——

Angiogenesis

EGFR

EGFR

——

——

1423077-49-9

510.96

C24H22ClF3N2O3S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 15 mg/mL (29.36 mM; 超声助溶 )

FC(F)(F)Oc1ccc(cc1)S(=O)(=O)NCCCN1c2ccccc2CCc2ccc(Cl)cc12

——

(-20℃)

With Ice Pack

≥ 2 years